麗珠醫藥集團股份有限公司
**LIVZON PHARMACEUTICAL GROUP INC.***
*(a joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock code: 1513)**

# VOLUNTARY ANNOUNCEMENT
# THE NOTICE OF DRUG CLINICAL TRIAL APPROVAL OF JP-1366 TABLET

Recently, Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the "**Company**") has received the Notice of Drug Clinical Trial Approval (Notice No.: 2026LP01115) issued by the National Medical Products Administration ("**NMPA**"), approving the Company to conduct a clinical trial of JP-1366 Tablet (the "**Drug**") for the indication of "in combination with appropriate antibiotics for the eradication of Helicobacter pylori." Relevant details are announced as follows:

## BASIC INFORMATION ABOUT THE DRUG

Drug name: JP-1366 Tablet

Dosage form: Tablet

Registration classification: Chemical Drug Category 2.4

Applied indication: In combination with appropriate antibiotics for the eradication of Helicobacter pylori

Approval conclusion: In accordance with the Drug Administration Law of the People's Republic of China (《中華人民共和國藥品管理法》) and related regulations, upon review, the application for JP-1366 Tablet accepted on 26 January 2026 complies with relevant requirements for drug

registration. Approval is granted to conduct clinical trials for the indication of "in combination with appropriate antibiotics for the eradication of Helicobacter pylori."

**DRUG DEVELOPMENT AND RELATED CONDITIONS**

JP-1366 Tablet is an innovative potassium-competitive acid blocker (P-CAB). The indication applied for in this clinical trial submission is in combination with appropriate antibiotics for the eradication of Helicobacter pylori.

For patients infected with Helicobacter pylori, the current mainstream clinical treatment regimen is quadruple therapy. The clinical trial submitted by the Company on this occasion aims to evaluate the efficacy and safety of a quadruple regimen consisting of JP-1366 Tablet (P-CAB), amoxicillin, clarithromycin, and bismuth potassium citrate (the "**Regimen**") for the eradication of Helicobacter pylori. In quadruple therapy, the role of the acid suppressant is critical. The Drug can act directly on the proton pump without requiring gastric acid activation, and is capable of simultaneously inhibiting both resting and activated proton pumps, featuring rapid onset of action as well as potent and sustained acid suppression, thereby demonstrating greater acid suppression advantages in this indication. Furthermore, under the Regimen, JP-1366 Tablet (acid suppressant), clarithromycin (antibiotic), and bismuth potassium citrate (bismuth agent) are all independently developed by the Company, reflecting the Company's deep pipeline layout and industrial synergy in this therapeutic area, and offering the potential to deliver a holistic clinical solution with superior therapeutic efficacy and greater quality stability.

Previously, the marketing authorisation application of the Drug for the treatment of reflux esophagitis was accepted in August 2025, and JP-1366 for injection for the treatment of peptic ulcer bleeding entered Phase II clinical trials in October 2025. For details, please refer to the Company's Voluntary Announcement on Acceptance of Application for Registration and Marketing Authorization of JP-1366 Tablets (Announcement No.: 2025-053) disclosed on Cninfo (www.cninfo.com.cn).

As at the date of this announcement, the cumulative direct R&D investment in JP-1366 Tablet is approximately RMB227.81 million.

**RISK WARNING**

In accordance with the relevant laws and regulations governing drug registration in China, following the receipt of the Notice of Drug Clinical Trial Approval, the drug is still required to undergo clinical trials and must be subject to review and approval by the NMPA before it can be manufactured and marketed. Due to the inherent nature of drug research and development, the progression from clinical trials to commercial production and market launch is a lengthy process involving multiple stages, and may be subject to various uncertainties. There are inherent uncertainties regarding the progress and outcomes of the clinical trials, as well as the future competitive landscape for the product. The Company will fulfill its information disclosure obligations in a timely manner based on the progress of research and development, and investors are advised to pay attention to investment risks.

By order of the Board
**Livzon Pharmaceutical Group Inc.***
**麗珠醫藥集團股份有限公司**
**Liu Ning**
*Company Secretary*

Zhuhai, China
10 April 2026

*As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (Vice Chairman); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.*

* *For identification purpose only*